Skip to main content
. 2013 Jun 4;19(4):351–358. doi: 10.1007/s13365-013-0173-y

Fig. 2.

Fig. 2

Mean (± SD) JCV DNA load in CSF in all HIV-positive patients (HAART-naïve and history of HAART groups combined). HIV-negative patients not included in analysis. Patients in the SOC group who opted to receive mefloquine at week 4 were not counted in the week 8 results. CSF cerebrospinal fluid, HAART highly active antiretroviral therapy, HIV human immunodeficiency virus, JCV JC virus, SOC standard of care